Table 1 Baseline characteristics of TNBC patients included in this study (N = 790).

From: A whole slide image-based risk score predicts prognosis and postmastectomy radiotherapy benefit in triple negative breast cancer patients

Characteristics

WCH cohort (n = 608)

TCGA cohort (n = 182)

P value (Chi-square)

histopathology image slides

1,199

218

 

histopathology image tiles

21,927

3,260

 

Age

< 0.001

 ≤40

140 (23.03%)

17 (9.34%)

 

 41–50

222 (36.51%)

51 (28.02%)

 

 51–60

164 (26.97%)

45 (24.73%)

 

 >60

82 (13.49%)

69 (37.91%)

 

Menopause

< 0.001

 No

335 (55.10%)

45 (24.72%)

 

 Yes

273 (44.90%)

113 (62.09%)

 

Unavailable

0 (0.00%)

24 (13.19%)

 

 Ki-67

 

 ≤20%

91 (14.97%)

 

 >20%

505 (83.06%)

 

 Unavailable

12 (1.97%)

 

Grade

 

 II

59 (9.70%)

 

 III

395 (64.97%)

 

 Unavailable

154 (25.33%)

 

T stage

0.006

 T1

180 (29.60%)

47 (25.82%)

 

 T2

331 (54.44%)

112 (61.54%)

 

 T3

33 (5.43%)

15 (8.24%)

 

 T4

28 (4.61%)

8 (4.40%)

 

 Unavailable

36 (5.92%)

0 (0.00%)

 

N stage

0.285

 N0

347 (57.07%)

108 (59.34%)

 

 N1

154 (25.33%)

47 (25.82%)

 

 N2

48 (7.90%)

18 (9.89%)

 

 N3

54 (8.88%)

9 (4.95%)

 

 Unavailable

5 (0.82%)

0 (0.00%)

 

NACT

< 0.001

 No

505 (83.06%)

182 (100.00%)

 

 Yes

103 (16.94%)

0 (0.00%)

 

ACT

< 0.001

 No

7 (1.15%)

108 (59.34%)

 

 Yes

601 (98.85%)

74 (40.66%)

 

PMRT

< 0.001

 No

396 (65.13%)

91 (50.00%)

 

 Yes

212 (34.87%)

91 (50.00%)

 

LVI

 

 No

428 (70.39%)

 

 Yes

37 (6.09%)

 

 Unavailable

143 (23.52%)

 

BCS

< 0.001

 No

554 (91.12%)

133 (73.08%)

 

 Yes

54 (8.88%)

49 (26.92%)

 
  1. *NACT neoadjuvant chemotherapy, ACT adjuvant chemotherapy, PMRT postmastectomy radiotherapy, LVI lymphovascular invasion, BCS breast-conserving surgery.